Navigation Links
Cenestra Health Issued Notice of Allowance: Expands Patent Range of High-Purity Omega-3 Fatty Acid Formulations
Date:9/19/2011

NEW HAVEN, Conn., Sept. 19, 2011 /PRNewswire/ -- The U.S. Patent and Trademark Office (USPTO) has issued a notice of allowance related to Cenestra Health's high-purity omega-3 fatty acid formulations and their methods of use.  The patent claims cover a range of high-purity omega-3 formulations including ethyl-ester, free fatty acid and triglyceride forms.  In 2010, Cenestra Health was issued U.S. Patent No. 7652068, entitled "Omega-3 Fatty Acid Formulations," covering its unique 4.1:1 ratio of eicosapentaenoic acid (EPA) to docosahexaenoic acid (DHA). The expanded patent range now covers high-purity omega-3 formulations with EPA:DHA ratios between about 3.5 to about 5:1. The patent claims also include methods of use to treat dyslipidemias including hypertriglyceridemia.

"The omega-3 landscape is in the midst of a major paradigm shift toward optimally formulated and very highly concentrated EPA/DHA products. The expanded patent claims allowed by the USPTO represent an important milestone in our scientific efforts as we advance novel investigational drugs into human clinical trials for the treatment of hypertriglyceridemia, central nervous system, and inflammatory disorders," commented Louis Sanfilippo, MD, a Managing Director of the company and Assistant Clinical Professor of Psychiatry at the Yale School of Medicine.  

Data obtained from third party laboratories support Cenestra Health's expanded range of proprietary formulations by demonstrating unique properties associated with different ratios of EPA:DHA.  Preclinical and clinical studies show the combination of high omega-3 concentration and these novel 'EPA:DHA ratio response effects' modulate key inflammatory cytokines, increase nerve growth factors, and lower triglycerides without increasing LDL cholesterol.  Cenestra Health is utilizing its biomarker targets and human clinical data to develop safe, new prescription medications for cardiovascular disease, depression and inflammation-based illnesses..

Omega-3-acid ethyl esters represent a class of medications called lipid-regulating agents. Prescription omega-3s are used together with lifestyle changes (i.e., weight loss, diet) to reduce the amount of triglycerides by decreasing the amount of fats made in the liver. The FDA has approved a number of prescription drugs to treat elevated triglycerides, including an omega-3 ethyl ester medication.

About Cenestra, LLC (D/B/A Cenestra Health)

Cenestra Health is a privately-held and unleveraged biopharmaceutical company based in New Haven, Connecticut. Cenestra Health was founded in 2005 to formulate, develop and market "best-in-class" proprietary natural products with applications in the OTC, medical food and pharmaceutical markets. Cenestra Health is focused on the clinical development of its late stage clinical drug candidates for the treatment of dyslipidemias and central nervous system disorders. Cenestra Health is planning to initiate  Phase 3 registrational trials in early 2012.

About Omega-3 Essential Fatty Acids

Omega-3 fatty acids are considered "essential" fatty acids (EFAs) as they are necessary to human health but cannot be produced by the body. The two major health promoting omega-3 polyunsaturated fatty acids are eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). EPA and DHA have been shown to promote good physical and emotional health, reduce the risk of cardiovascular disease, and exert powerful anti-inflammatory effects. Omega-3 prescriptions in the United States alone accounted for over $1 billion dollars in sales in 2010.

Statements made in this press release should not to be construed as making any specific claim or claims in the diagnosis, prevention or treatment of any disease or disorder but  may relate to historical facts and information that reflect forward looking statements based on Cenestra Health's intellectual property and scientific data.    

Investor Contact:  

Louis Sanfilippo, M.D., Managing Director
Cenestra Health
234 Church Street, Suite 302
New Haven, Connecticut 06510

Telephone: 203-362-8919

Email: investor.relations@cenestrahealth.com

Website: www.cenestrahealth.com

US Patent No. 7652068/Omega-3 Fatty Acid Formulations


'/>"/>
SOURCE Cenestra Health
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Healthpoint Biotherapeutics to Present at UBS Global Life Sciences Conference
2. GNS Healthcare, Inc Collaborates with Nationally Ranked Hospital to Predict Adverse Drug Events and Hospital Readmissions
3. Health fears over CO2 storage are unfounded, study shows
4. Enterologics Completes Acquisition of BioBalance Corp and Probiotic Product From New York Health Care, Inc
5. Tengion to Present at Rodman & Renshaw 13th Annual Healthcare Conference
6. Anadys Pharmaceuticals Updates Its Presentation Date at the Stifel Nicolaus Healthcare Conference
7. Chimerix to Present at Stifel Nicolaus 2011 Healthcare Conference
8. Clinical Integration Enables Leading Health Systems to Deliver Higher Quality, Cost-Effective Care
9. Omeros to Present at Rodman and Renshaw 13th Annual Healthcare Conference
10. Amsterdam Molecular Therapeutics Licenses Additional Novel Gene Therapy Vectors from National Institutes of Health
11. Neuralstem President and CEO to Present at the 2011 Stifel Nicolaus Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2017)... 23, 2017 Atlas Genetics Ltd., the ... its Series D financing, raising $35 million from a syndicate ... Biotech. ... Development of the Atlas Genetics io® system has been completed ... test announced in February 2016.  This new Series D equity ...
(Date:1/21/2017)... ... January 20, 2017 , ... G&L Scientific Inc, ... industry ( http://www.gandlscientific.com ), has announced the opening of new offices in Cambridge, ... consultants and contractors. This is the latest step in G&L’s expansion of its ...
(Date:1/21/2017)... Aratana Therapeutics, Inc. (NASDAQ: PETX ... development and commercialization of innovative biopharmaceutical products for companion ... North America 2016. ... on the FDA approval of three innovative therapeutics in ... (capromorelin oral solution) and NOCITA ® (bupivacaine liposome ...
(Date:1/20/2017)... -- http://www.Financialbuzz.com - According to ... of death worldwide. There were 8.2 million cancer related ... deaths increased gradually over time, the death rates have ... cancers continues to drive demand of biological therapies for ... Insights, Inc. cancer biological therapy market size was USD 61.3 ...
Breaking Biology Technology:
(Date:12/15/2016)... Advancements in biometrics will radically ... wellbeing (HWW), and security of vehicles by ... vehicles begin to feature fingerprint recognition, iris ... monitoring, brain wave monitoring, stress detection, fatigue ... detection. These will be driven by built-in, ...
(Date:12/8/2016)... 2016 Market Research Future published a half cooked research ... Biometric Security and Service Market is expected to grow over the ... Market Highlights: ... Mobile Biometric Security and Service Market ... need of authentication and security from unwanted cyber threats. The increasing ...
(Date:12/7/2016)...   Avanade is helping Williams Martini Racing, ... history, exploit biometric data in order to critically analyse ... competitive edge against their rivals after their impressive, record-breaking ... has worked with Williams during the 2016 season to ... rate, breathing rate, temperature and peak acceleration) for key ...
Breaking Biology News(10 mins):